Cbe, ma (Oxon), mbchB, bsc (Hons), msc, PhD, md, dsc, frcp (Glasgow,Edinburgh and London), frcgp (hon), fcanSci, fmedSci

International

• 
  Pan European Trial of Adjuvant Chemotherapy for Colorectal Cancer – Trial Steering Committee, UK Chairman (1995-1998)
  
• 
  European Society for Medical Oncology, Chairman of Scientific Committee - responsible for arranging and ensuring a high scientific content of ESMO Athens meetings (1998)
  
• 
  American Society for Clinical Oncology - international liaison committee of senior European and American oncologists linking ESMO and ASCO meetings (1998)
  
• 
  International Working Party on Colorectal Cancer: this group consists of senior academics from USA and each European Country with an interest in the treatment of colorectal cancer.(1999)
  
• 
  EORTC, Gastro-intestinal Study Group, Member - responsible for trans-European studies in a range of gastro-intestinal cancer. (1998 – present)
  
• 
  Editor-in-Chief, Annals of Oncology; scientific journal of European Society of Medical Oncology and Europe's leading clinical cancer journal. (1999 – present)
  
• 
  US National Institute of Health Colorectal Cancer Research Strategy Group – overseas member, 2000
  
• 
  Co-Chairman, Scientific Steering Committee for centenary celebration of Entente Cordiale – “Today’s Science, Tomorrow’s Patient” 2003 – 2005)
  
• 
  US National Cancer Institute – Translational Research Working Group (sole overseas member) 2005-2007
  
• 
  European Society of Medical Oncology, Presidential Cycle, 2008-2014
  
• 
  Chairman of INDOX – www.indox.org.uk – 2005 to date
  
• 
  Chairman of AfrOx – www.afrox.org – 2007 – to date
  
• 
  Member of International Scientific Advisory Board for Center for Translational Molecular Medicine, The Netherlands – 2008 (present distribution of 500 million Euros)
  
• 
  Member of International Assessment Committee for Research Hospital Fund of Canadian Foundation for Innovation: distribution of $500 million, 2008
  
• 
  Member of Advisory Board of the Centre for Cancer Biomedicine, The Norwegian Radium Hospital, Norway, 2008 - date.
  
• 
  Member of Scientific Advisory Board of Institut Gustav Roussy, Paris (2009- to date)
  
• 
  Supreme Council of Health, Qatar (2009 – 10)
  
• 
  Chairman, OxOnics – Asia-Pacific Oncology development company (2011 – present)
  

CLINICAL AND SCIENTIFIC LEADERSHIP

Working in partnership with Professor Alan Rickinson FRS. I established the CRC Institute for Cancer Studies in University of Birmingham, built the scientific establishment from around 50-60 staff to 150-200 and secured funding to construct a new laboratory to house the expanded workforce. I supported construction of a new cancer hospital in Birmingham, forged a series of innovative clinical practices, founded clinical gene therapy in Birmingham and spun out a small biotech company, COBRA Therapeutics.

Appointment to the Rhodes Chair of Cancer Therapeutics and Clinical Pharmacology (October, 2001), University of Oxford has allowed me to work with Sir John Bell to build a new Institute for Cancer Medicine in Oxford, (£60 million) contiguous with the new cancer hospital (£125 million) on the Churchill Biomedical Campus. My recent appointed as Chief Research Advisor to the Sidra Medical and Research Centre ($3 billion build and design project) has allowed me to share the vision of Her Highness Sheikha Mozah in her desire to build a world class research environment in Doha. This represented an extraordinary opportunity to develop a world-class research centre with a particular emphasis on translating findings from basic science into novel diagnostic or therapeutic agents for patients who suffers from chronic disease burden of Qatar (cancer, diabetes and cardiovascular disease).I have returned to Oxford as Professor of Cancer Medicine, Radcliffe Dept of medicine and Chief medical Officer of Oxford Cancer Biomarker
This work was recognised by award of CBE (2002) by HM the Queen.

CLINICAL DUTIES and COLORECTAL CANCER RESEARCH

In Oxford I have joined the multidisciplinary gastro-intestinal cancer team, established a contract with the Danish Government to see and treat their refractory liver cancer patients, developed a gastrointestinal cancer study group within my Clinical Trials Unit and have accrued large patient numbers to local, national and international studies. Richard Gray and I ran QUASAR, a trial of adjuvant chemotherapy in colorectal cancer which successfully recruited 8500 patients in 8 years making it one of the largest and therefore potentially most influential cancer trials in the world. This has continued in Oxford with VICTOR, a placebo-controlled study of a selective COX-2 inhibitor, rofecoxib in an adjuvant setting for CRC which has recruited 2,500 patients. QUASAR 2 (3,750 patients) will compare standard chemotherapy versus Capecitabine and Bevacizumab, a regime which was developed in our own unit. This work has established the UK and my Unit as international leaders in the field of treatment and research into colorectal cancer. More recently, we have extended this work through collaboration with Prof Ian Tomlinson into the field of Genome Wide Association studies, with some notable success. I joined the Al Amal Hospital in Doha as Consultant Medical Oncologist and have been charged by Her Highness Sheikha Mozah with developing a cancer plan for the Nation.

Contribution to the field of colorectal cancer research and treatment was recognised in 1999 by the award of the 2^nd International GI Cancer prize by the Institute for Drug Development and European Association for Research into Gastrointestinal Cancer and the ESMO award, 2006.

TRANSLATIONAL CANCER RESEARCH

I have been involved in cancer drug development for 30 years and established a phase I Trials Unit in the University of Birmingham, working later with Professor Lawrence Young to develop an MRC-funded virus-based gene therapy programme. I joined the Oxford Cancer Centre experimental trials group working with consultant colleagues, Prof Mark Middleton and Professor Adrian Harris with approximately 200-300 patients referred per annum for consideration of novel therapy with signal transduction inhibitors from the Pharma industry and our own account gene therapy programme (preclinical lead is Professor Len Seymour). I have conducted approximately 30 phase 1 trials.

Contribution to the field of gene therapy was recognised by award of the NHS’ first Nye Bevan award for Research Excellence.

Download 443.19 Kb.

Share with your friends: